Kalorama: Applications are Key as Sequencing Market Climbs to $3.8 Billion

News provided by

Sep 21, 2016, 08:41 ET

NEW YORK, Sept. 21, 2016 /PRNewswire/ -- According to Kalorama Information, the sequencing market has evolved to the point where it is experiencing rapid growth, with an estimated $3.8 billion in product revenues in 2015. This estimate includes both sequencing instruments plus consumables, and also service revenue such as from extended instrument service contracts. New uses of sequencing, especially clinical uses, are driving sales. The healthcare market research firm's report, Next-Generation Sequencing Markets, analyzes the current and potential world market for next-generation sequencing.

Next-Generation Sequencing Markets (Systems, Consumables, Services, Competitive Analysis, Trends, Platforms) can be found at Kalorama Information: http://www.kaloramainformation.com/Generation-Sequencing-Systems-10290041/?productid=10290041.

"Clinical applications of DNA sequencing are being developed and commercialized," said Bruce Carlson, Publisher of Kalorama Information. "The major clinical market for sequencing continues to be oncology, followed by genetic or inherited disorders, and sequencing is being applied to other clinical applications as well."

Research that eventually led to the emergence of next-generation sequencing ten years ago actually started as early as the 1970s. The road to where the sequencing market is today has been long and hard, with improvements in sequencing technology still needed to make sequencing-based diagnostic tests widely available and used by all physicians. However, the sequencing field has entered an exciting time where it is now becoming possible to realize some of the potential benefits long dreamed about by researchers and companies in this field.

DNA sequencing has successfully penetrated the research market. Today, this market is large, and is expected to continue to grow, despite funding issues and other challenges. In addition, technology advances in knowledge of the genome, and in DNA sequencing technology/platforms, will continue to fuel the growth of diagnostic applications of next-generation sequencing in clinical laboratories and companies having laboratories that are Clinical Laboratory Improvement Amendments (CLIA) certified, and also in in vitro diagnostic (IVD) companies that sell kits to clinical labs.

DNA sequencing is also penetrating the clinical diagnostic market. Most currently available clinical tests based on next-generation sequencing are laboratory-developed tests (LDTs). The first next-generation sequencing system and in vitro diagnostic tests have been cleared by the FDA, and more will follow. The next-generation sequencing clinical diagnostic market is poised for continued rapid growth over the next several years.

Next-generation sequencing is increasingly being used in the field of personalized medicine and companion diagnostics. For example, in oncology, pharmaceutical companies are developing and commercializing a growing number of targeted therapies. This has generated a need for assays that detect the presence or absence of increasingly more genetic markers, all from a small sample of tissue. In other words, multiplexed assays and/or panels are needed. This, in turn, has led to increased interest in technologies such as next-generation sequencing, which can be used to interrogate a large number of genes in a single assay. As diagnostic companies develop assays based on next-generation sequencing, the focus is on assays that generate actionable results – where there is sufficient clinically validated information on the significance of the genetic change so that the results are useful in helping a clinician make a treatment decision. As a result, many diagnostic assays are based on targeted sequencing approaches that focus on genes for which the clinical utility of genetic changes is known.

Companies in the next-generation sequencing market have attracted major investments. Since the beginning of 2015 alone, companies have raised billions in investments. Many pharmaceutical companies have entered into deals with next-generation sequencing companies. These include acquisitions or other deals to gain access or enhance their own internal sequencing capabilities and expertise, and also deals with diagnostic companies who can develop companion diagnostic or other tests for use with therapies being developed by pharmaceutical companies. Kalorama profiles 70 companies in its report, including Abbott Laboratories; Beckman Coulter, Inc. (a subsidiary of Danaher Corporation); Becton, Dickinson and Company (BD); Illumina, Inc.; Laboratory Corporation of America (LabCorp); Pacific Biosciences of California, Inc.; QIAGEN N.V.; Roche; Siemens Healthcare Diagnostics; and Thermo Fisher Scientific, Inc.

Next-Generation Sequencing Markets examines the segments of the sequencing market, including sequencing instruments plus consumables and also service revenue such as from extended instrument service contracts, with analysis of the full sequencing market including: worldwide sequencing market product revenues (instruments and consumables), 2015 and 2020; sequencing market, worldwide, 2015 and 2020 (instrument revenue, consumables revenue, services revenue, total market); market share of sequencing market, by company (instruments, consumables, services relating to supporting products); sequencing market by geographical region, worldwide, 2015 and 2020 (North America, Europe, Asia, rest of world, total market); next-generation sequencing system ownership by country, percentage (United States, China, Germany, U.K., South Korea, Spain, Canada, France, Australia, Netherlands, Italy, Taiwan, Brazil, Japan, India, Sweden, Belgium, Denmark, Switzerland, Singapore, Saudi Arabia, others); next-generation sequencing system ownership by brand (HiSeq2000, Genome Analyser, Roche 454, ABI SOLiD, Ion Torrent, MiSeq, Ion Proton, Pacific Biosciences, Oxford Nanopore MinION, Polonator, NextSeq); percent of end users (academic & government versus commercial, non-profit & hospital), 2014, 2015, and 2018 (projected); research sequencing market – types of sequencing: targeted or whole exome sequencing versus de novo or whole genome sequencing (2015); clinical sequencing market by disease category, 2015, percentage (genetic testing/inherited disorders, other disorders); clinical sequencing market by disease category, 2020, percentage (oncology, genetic testing/inherited disorders, infectious disease, other disorders); and investments in next-generation sequencing companies, 2015 and first half of 2016.

Please link any media or news references to our reports or data to http://www.kaloramainformation.com/.

About Kalorama Information

Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.

We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.

Contact:
Bruce Carlson
(212) 807-2622
[email protected]
www.KaloramaInformation.com

Logo - http://photos.prnewswire.com/prnh/20150831/262422LOGO

SOURCE Kalorama Information